Timing of Breast Cancer Related Lymphedema Development Over 3 Years: Observations from a Large, Prospective...

Area of Science:

• Oncology
• Lymphedema Research
• Clinical Trials

Background:

• The PREVENT trial investigated progression from subclinical breast cancer-related lymphedema (sBCRL) to chronic breast cancer-related lymphedema (cBCRL).
• Bioimpedance spectroscopy (BIS) and tape measure (TM) were used for sBCRL assessment.
• A 92% risk reduction in developing cBCRL was observed with intervention.

Purpose of the Study:

• To analyze the timing of sBCRL and cBCRL development after breast cancer treatment.
• To evaluate the long-term risk of lymphedema progression.

Main Methods:

• 919 women at risk for cBCRL were screened up to 36 months post-treatment using BIS or TM.
• Patients diagnosed with sBCRL received a 4-week compression sleeve intervention.
• Time to detection was analyzed at 3-month intervals.

Main Results:

• 209 patients developed sBCRL; 30 progressed to cBCRL post-intervention.
• Over half of sBCRL cases were detected within 9 months of treatment.
• 39 patients progressed to cBCRL without prior sBCRL diagnosis or intervention.

Conclusions:

• Patients remain at risk for sBCRL and cBCRL progression for years after breast cancer treatment.
• Early detection and intervention for sBCRL decrease the likelihood of cBCRL.
• Minimum 3-year monitoring post-treatment is recommended, with emphasis on the initial 9 months.